Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Dopamine D2 receptor | Starlite/ChEMBL | References |
Homo sapiens | glutamate receptor, ionotropic, N-methyl D-aspartate 1 | Starlite/ChEMBL | References |
Rattus norvegicus | Adrenergic receptor alpha-1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma japonicum | ko:K04207 neuropeptide Y receptor Y5, putative | Dopamine D2 receptor | 444 aa | 386 aa | 19.7 % |
Echinococcus multilocularis | serotonin receptor | Dopamine D2 receptor | 444 aa | 428 aa | 31.3 % |
Loa Loa (eye worm) | hypothetical protein | Dopamine D2 receptor | 444 aa | 433 aa | 21.2 % |
Schistosoma japonicum | ko:K04136 adrenergic receptor, alpha 1b, putative | Dopamine D2 receptor | 444 aa | 440 aa | 30.0 % |
Echinococcus granulosus | biogenic amine 5HT receptor | Dopamine D2 receptor | 444 aa | 429 aa | 31.7 % |
Onchocerca volvulus | RB1-inducible coiled-coil protein 1 homolog | Dopamine D2 receptor | 444 aa | 474 aa | 23.4 % |
Echinococcus granulosus | g protein coupled receptor | Dopamine D2 receptor | 444 aa | 457 aa | 21.0 % |
Onchocerca volvulus | Dopamine D2 receptor | 444 aa | 418 aa | 23.0 % | |
Schistosoma japonicum | Octopamine receptor, putative | Dopamine D2 receptor | 444 aa | 456 aa | 29.4 % |
Onchocerca volvulus | Glycoprotein hormone beta 5 homolog | Dopamine D2 receptor | 444 aa | 476 aa | 24.2 % |
Schistosoma mansoni | biogenic amine receptor | Dopamine D2 receptor | 444 aa | 452 aa | 30.1 % |
Echinococcus multilocularis | g protein coupled receptor | Dopamine D2 receptor | 444 aa | 465 aa | 21.5 % |
Schistosoma mansoni | biogenic amine (dopamine) receptor | Dopamine D2 receptor | 444 aa | 494 aa | 26.3 % |
Schistosoma mansoni | amine GPCR | Dopamine D2 receptor | 444 aa | 424 aa | 32.1 % |
Schistosoma mansoni | muscarinic acetylcholine (GAR) receptor | Dopamine D2 receptor | 444 aa | 487 aa | 23.8 % |
Schistosoma japonicum | ko:K04145 dopamine receptor D2, putative | Dopamine D2 receptor | 444 aa | 432 aa | 30.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | glutamate receptor NMDA | 0.0095 | 0.7233 | 0.8937 |
Echinococcus multilocularis | glutamate receptor, ionotrophic, AMPA 3 | 0.0029 | 0.0861 | 0.1063 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.01 | 0.7674 | 0.9482 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.0029 | 0.0861 | 0.1063 |
Echinococcus multilocularis | glutamate receptor 2 | 0.0029 | 0.0861 | 0.1063 |
Echinococcus granulosus | nmda type glutamate receptor | 0.01 | 0.7674 | 0.9482 |
Loa Loa (eye worm) | glutamate receptor 1 | 0.0024 | 0.0419 | 0.5 |
Echinococcus multilocularis | glutamate receptor NMDA | 0.0095 | 0.7233 | 0.8937 |
Echinococcus granulosus | glutamate receptor ionotrophic AMPA 3 | 0.0029 | 0.0861 | 0.1063 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.0029 | 0.0861 | 0.1063 |
Brugia malayi | Glutamate receptor 2 precursor | 0.0024 | 0.0419 | 0.5 |
Echinococcus multilocularis | glutamate receptor 2 | 0.0024 | 0.0419 | 0.0518 |
Echinococcus multilocularis | glutamate (NMDA) receptor subunit | 0.0024 | 0.0419 | 0.0518 |
Echinococcus granulosus | glutamate receptor 2 | 0.0029 | 0.0861 | 0.1063 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.0029 | 0.0861 | 0.1063 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0104 | 0.8094 | 1 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.0029 | 0.0861 | 0.1063 |
Loa Loa (eye worm) | glutamate receptor 2 | 0.0024 | 0.0419 | 0.5 |
Echinococcus granulosus | glutamate NMDA receptor subunit | 0.0024 | 0.0419 | 0.0518 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0104 | 0.8094 | 1 |
Echinococcus granulosus | Glutamate receptor ionotropic kainate 2 | 0.0029 | 0.0861 | 0.1063 |
Brugia malayi | Glutamate receptor 1 precursor | 0.0024 | 0.0419 | 0.5 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 2 | 0.0029 | 0.0861 | 0.1063 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.026 uM | Concentration required for 50% Inhibition of responses at cloned NR1A/2AB NMDA expressed in Xenopus oocytes | ChEMBL. | 10978188 |
IC50 (binding) | = 0.026 uM | Concentration required for 50% Inhibition of responses at cloned NR1A/2AB NMDA expressed in Xenopus oocytes | ChEMBL. | 10978188 |
IC50 (binding) | = 9.9 uM | Displacement of [3H]-raclopride at Dopamine receptor D2 in brain striata (n=1) | ChEMBL. | 10978188 |
IC50 (binding) | = 9.9 uM | Displacement of [3H]-raclopride at Dopamine receptor D2 in brain striata (n=1) | ChEMBL. | 10978188 |
IC50 (binding) | = 17 uM | Displacement of [3H]-prazosin at alpha-1 adrenergic receptor in rat brain cortices (n=1) | ChEMBL. | 10978188 |
IC50 (binding) | = 17 uM | Displacement of [3H]-prazosin at alpha-1 adrenergic receptor in rat brain cortices (n=1) | ChEMBL. | 10978188 |
IC50 (binding) | > 100 uM | Concentration required for 50% Inhibition of responses at cloned NR1A/2A NMDA expressed in Xenopus oocytes | ChEMBL. | 10978188 |
IC50 (binding) | > 100 uM | Concentration required for 50% Inhibition of responses at cloned NR1A/2C NMDA expressed in Xenopus oocytes | ChEMBL. | 10978188 |
IC50 (binding) | > 100 uM | Concentration required for 50% Inhibition of responses at cloned NR1A/2A NMDA expressed in Xenopus oocytes | ChEMBL. | 10978188 |
IC50 (binding) | > 100 uM | Concentration required for 50% Inhibition of responses at cloned NR1A/2C NMDA expressed in Xenopus oocytes | ChEMBL. | 10978188 |
MED (functional) | > 30 mg kg-1 | Lowest oral dose that shows significant potentiation of total contraversive rotations over 3 h caused by L-DOPA (10mg/kg, sc) in 6-hydroxydopamine-lesioned rats (n=8)administered perorally | ChEMBL. | 10978188 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.